GlassScriptPhysician profile
Robert F Ennis
NPI 1366647729
$68,543.12
in general payments reported to CMS, 2019-2025
39 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $1,074 · 2021: $719 · 2022: $720 · 2023: $2,196 · 2024: $811 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63,636.46 | 2019-2024 | Trulicity, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,105.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $545.80 | 2019-2025 | Prolia, Evenity, Repatha |
| Corcept Therapeutics | $453.19 | 2019-2025 | Korlym |
| Antares Pharma, INC. | $413.28 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $337.78 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $307.83 | 2019-2023 | Farxiga |
| Abbott Laboratories | $240.19 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $204.95 | 2019-2023 | |
| Amarin Pharma, INC. | $162.61 | 2020-2021 | |
| Insulet Corporation | $149.76 | 2020-2025 | Omnipod |
| Horizon Therapeutics Plc | $127.72 | 2023 | Tepezza |
| Radius Health, INC. | $121.87 | 2019-2023 | Tymlos |
| Tandem Diabetes Care, INC. | $93.53 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $62.22 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.